• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table H.2Treatment effects of aspirin in all women with pregnancy-related hypertension who are at risk of developing pre-eclampsia

OutcomeModel valueDistributionLN(mean)Lower CIUpper CIStandard errorSource
Pre-eclampsia0.90Lognormal−0.110.840.970.04Askie et al.42
Delivery < 34 weeks0.91Lognormal−0.090.830.980.04Askie et al.42
Baby death before discharge0.90Lognormal−0.110.811.030.06Askie et al.42
SGA0.90Lognormal−0.110.811.010.06Askie et al.42
Any of the above0.90Lognormal−0.110.850.960.03Askie et al.42

From: Appendix H, Cost effectiveness of aspirin compared with no aspirin in preventing pre-eclampsia in women at risk of developing pre-eclampsia

Cover of Hypertension in Pregnancy
Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy.
NICE Clinical Guidelines, No. 107.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2010 Aug.
Copyright © 2011, Royal College of Obstetricians and Gynaecologists.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.